Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Obituary: J. David LEander, Ph.D. : (April 8, 1944-November 14, 2014).

Witkin JM, Gleason SD, Carter RB, Dykstra LA.

Psychopharmacology (Berl). 2015 Apr;232(7):1175-6. doi: 10.1007/s00213-015-3885-2. Epub 2015 Feb 21. No abstract available.

PMID:
25697862
2.

Fluid-containing emphysematous bullae: a spectrum of illness.

Chandra D, Rose SR, Carter RB, Musher DM, Hamill RJ.

Eur Respir J. 2008 Aug;32(2):303-6. doi: 10.1183/09031936.00158807.

3.

Pharmacology of 2-[4-(4-chloro-2-fluorophenoxy)phenyl]-pyrimidine-4-carboxamide: a potent, broad-spectrum state-dependent sodium channel blocker for treating pain states.

Ilyin VI, Pomonis JD, Whiteside GT, Harrison JE, Pearson MS, Mark L, Turchin PI, Gottshall S, Carter RB, Nguyen P, Hogenkamp DJ, Olanrewaju S, Benjamin E, Woodward RM.

J Pharmacol Exp Ther. 2006 Sep;318(3):1083-93. Epub 2006 May 25.

PMID:
16728593
4.

V102862 (Co 102862): a potent, broad-spectrum state-dependent blocker of mammalian voltage-gated sodium channels.

Ilyin VI, Hodges DD, Whittemore ER, Carter RB, Cai SX, Woodward RM.

Br J Pharmacol. 2005 Mar;144(6):801-12.

5.

Phenoxyphenyl pyridines as novel state-dependent, high-potency sodium channel inhibitors.

Shao B, Victory S, Ilyin VI, Goehring RR, Sun Q, Hogenkamp D, Hodges DD, Islam K, Sha D, Zhang C, Nguyen P, Robledo S, Sakellaropoulos G, Carter RB.

J Med Chem. 2004 Aug 12;47(17):4277-85.

PMID:
15293999
6.

3-(4-phenoxyphenyl)pyrazoles: a novel class of sodium channel blockers.

Yang J, Gharagozloo P, Yao J, Ilyin VI, Carter RB, Nguyen P, Robledo S, Woodward RM, Hogenkamp DJ.

J Med Chem. 2004 Mar 11;47(6):1547-52.

PMID:
14998340
7.

Protective efficacy of neuroactive steroids against cocaine kindled-seizures in mice.

Kaminski RM, Gasior M, Carter RB, Witkin JM.

Eur J Pharmacol. 2003 Aug 8;474(2-3):217-22.

PMID:
12921865
8.

Development of a presynaptic 5-HT1A antagonist.

Mattson RJ, Catt JD, Sloan CP, Gao Q, Carter RB, Gentile A, Mahle CD, Matos FF, McGovern R, VanderMaelen CP, Yocca FD.

Bioorg Med Chem Lett. 2003 Jan 20;13(2):285-8.

PMID:
12482441
9.
10.
11.

Modification of behavioral effects of drugs in mice by neuroactive steroids.

Ungard JT, Beekman M, Gasior M, Carter RB, Dijkstra D, Witkin JM.

Psychopharmacology (Berl). 2000 Mar;148(4):336-43.

PMID:
10928304
12.

Neuroactive steroids attenuate cocaine-induced sucrose intake in rats, but not cocaine-induced hyperactivity in mice.

Vanover KE, Suruki M, Huber M, Wilent WB, Carter RB.

Psychopharmacology (Berl). 2000 Apr;149(3):269-76.

PMID:
10823408
14.

Response-rate suppression in operant paradigm as predictor of soporific potency in rats and identification of three novel sedative-hypnotic neuroactive steroids.

Vanover KE, Edgar DM, Seidel WF, Hogenkamp DJ, Fick DB, Lan NC, Gee KW, Carter RB.

J Pharmacol Exp Ther. 1999 Dec;291(3):1317-23.

PMID:
10565857
15.

Pharmacological evaluation of a modified conflict procedure: punished drinking in non-water-deprived rats.

Vanover KE, Robledo S, Huber M, Carter RB.

Psychopharmacology (Berl). 1999 Aug;145(3):333-41.

PMID:
10494583
16.

Reinforcing and discriminative stimulus effects of the neuroactive steroids pregnanolone and Co 8-7071 in rhesus monkeys.

Rowlett JK, Winger G, Carter RB, Wood PL, Woods JH, Woolverton WL.

Psychopharmacology (Berl). 1999 Jul;145(2):205-12.

17.

Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders.

Gasior M, Carter RB, Witkin JM.

Trends Pharmacol Sci. 1999 Mar;20(3):107-12. Review.

PMID:
10203866
18.

Positive allosteric modulators of the GABA(A) receptor: differential interaction of benzodiazepines and neuroactive steroids with ethanol.

Vanover KE, Suruki M, Robledo S, Huber M, Wieland S, Lan NC, Gee KW, Wood PL, Carter RB.

Psychopharmacology (Berl). 1999 Jan;141(1):77-82.

PMID:
9952068
19.

Substituted 3beta-phenylethynyl derivatives of 3alpha-hydroxy-5alpha-pregnan-20-one: remarkably potent neuroactive steroid modulators of gamma-aminobutyric acidA receptors.

Hawkinson JE, Acosta-Burruel M, Yang KC, Hogenkamp DJ, Chen JS, Lan NC, Drewe JA, Whittemore ER, Woodward RM, Carter RB, Upasani RB.

J Pharmacol Exp Ther. 1998 Oct;287(1):198-207.

PMID:
9765338
20.

Synthesis of 7,8-(methylenedioxy)-1-phenyl-3,5-dihydro-4H-2, 3-benzodiazepin-4-ones as novel and potent noncompetitive AMPA receptor antagonists.

Wang Y, Konkoy CS, Ilyin VI, Vanover KE, Carter RB, Weber E, Keana JF, Woodward RM, Cai SX.

J Med Chem. 1998 Jul 2;41(14):2621-5.

PMID:
9651166
21.

Reversal of behavioral effects of pentylenetetrazol by the neuroactive steroid ganaxolone.

Beekman M, Ungard JT, Gasior M, Carter RB, Dijkstra D, Goldberg SR, Witkin JM.

J Pharmacol Exp Ther. 1998 Mar;284(3):868-77.

PMID:
9495844
22.

Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam.

Gasior M, Carter RB, Goldberg SR, Witkin JM.

J Pharmacol Exp Ther. 1997 Aug;282(2):543-53.

PMID:
9262314
23.

CCD-3693: an orally bioavailable analog of the endogenous neuroactive steroid, pregnanolone, demonstrates potent sedative hypnotic actions in the rat.

Edgar DM, Seidel WF, Gee KW, Lan NC, Field G, Xia H, Hawkinson JE, Wieland S, Carter RB, Wood PL.

J Pharmacol Exp Ther. 1997 Jul;282(1):420-9.

PMID:
9223583
24.

Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor.

Carter RB, Wood PL, Wieland S, Hawkinson JE, Belelli D, Lambert JJ, White HS, Wolf HH, Mirsadeghi S, Tahir SH, Bolger MB, Lan NC, Gee KW.

J Pharmacol Exp Ther. 1997 Mar;280(3):1284-95.

PMID:
9067315
25.

3 alpha-Hydroxy-3 beta-(phenylethynyl)-5 beta-pregnan-20-ones: synthesis and pharmacological activity of neuroactive steroids with high affinity for GABAA receptors.

Upasani RB, Yang KC, Acosta-Burruel M, Konkoy CS, McLellan JA, Woodward RM, Lan NC, Carter RB, Hawkinson JE.

J Med Chem. 1997 Jan 3;40(1):73-84.

PMID:
9016330
26.

Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug.

Taylor DP, Carter RB, Eison AS, Mullins UL, Smith HL, Torrente JR, Wright RN, Yocca FD.

J Clin Psychiatry. 1995;56 Suppl 6:3-11. Review.

PMID:
7649970
29.

Effects of picenadol (LY150720) and its stereoisomers on electric shock titration in the squirrel monkey.

Carter RB, Dykstra LA.

J Pharmacol Exp Ther. 1985 Aug;234(2):299-306.

PMID:
4020674
31.
33.

Evidence that taste aversion learning induced by l-5-hydroxytryptophan is mediated peripherally.

Ervin GN, Carter RB, Webster EL, Moore SI, Cooper BR.

Pharmacol Biochem Behav. 1984 May;20(5):799-802.

PMID:
6610880
34.

Effects of norepinephrine and serotonin uptake inhibitors on the schedule-controlled behavior of the pigeon.

Leander JD, Carter RB.

Pharmacol Biochem Behav. 1984 Mar;20(3):391-5.

PMID:
6608736
35.

Descartes' methodological transformation of Homo sapiens into Homo faber.

Carter RB.

Sudhoffs Arch. 1984;68(2):225-9. No abstract available.

PMID:
6241364
36.

Acute tolerance to the discriminative stimulus properties of morphine.

Witkin JM, Dykstra LA, Carter RB.

Pharmacol Biochem Behav. 1982 Aug;17(2):223-8.

PMID:
7134234
37.

Attenuation of normeperidine's suppressing effect on schedule-controlled behavior.

Leander JD, Carter RB.

Eur J Pharmacol. 1982 Jun 16;81(1):107-10.

PMID:
7117363
38.

Gilbert and Descartes: the science of conserving the compound body.

Carter RB.

Z Allg Wissenschaftstheor. 1982;13(2):224-33. No abstract available.

PMID:
11636296
39.

Discriminative stimulus properties of naloxone.

Carter RB, Leander JD.

Psychopharmacology (Berl). 1982;77(4):305-8.

PMID:
6291084
40.

Evidence for a peripheral effect of sertonin or metabolites in 5-hydroxytryptophan-induced hypothermia.

Carter RB, Leander JD.

Neuropharmacology. 1980 Aug;19(8):777-84. No abstract available.

PMID:
6968413
41.

Discriminative stimulus properties of d-amphetamine-pentobarbital combinations.

Witkin JM, Carter RB, Dykstra LA.

Psychopharmacology (Berl). 1980;68(3):269-76. No abstract available.

PMID:
6771810
42.

Role of peripheral mechanisms in the behavioral effects of 5-hydroxytryptophan.

Carter RB, Dykstra LA, Leander JD, Appel JB.

Pharmacol Biochem Behav. 1978 Aug;9(2):249-53.

PMID:
309609
43.

LSD and 5-HTP: tolerance and cross-tolerance relationships.

Carter RB, Appel JB.

Eur J Pharmacol. 1978 Jul 15;50(2):145-8.

PMID:
308008
44.

Blockade of the behavioral effects of 5-HTP by the decarboxylase inhibitor Ro 4-4602.

Carter RB, Appel JB.

Pharmacol Biochem Behav. 1976 Apr;4(4):407-9.

PMID:
935212
45.

The intramandibular course of the inferior alveolar nerve.

Carter RB, Keen EN.

J Anat. 1971 Apr;108(Pt 3):433-40. No abstract available.

46.

Medical Grievances and Suggested Remedies.

Carter RB.

Hospital (Lond 1886). 1900 Nov 17;29(738):126-127. No abstract available.

47.

Latent Squint.

Carter RB.

Hospital (Lond 1886). 1896 Jun 6;20(506):156-157. No abstract available.

48.

On Modern Progress in Ophthalmic Medicine and Surgery: Latent Squint.

Carter RB.

Hospital (Lond 1886). 1896 Mar 7;19(493):375. No abstract available.

49.

On Modern Progress in Ophthalmic Medicine and Surgery: Latent Squint (Heterophoria).

Carter RB.

Hospital (Lond 1886). 1896 Feb 22;19(491):341. No abstract available.

50.

On Modern Progress in Ophthalmic Medicine and Surgery: Squint.

Carter RB.

Hospital (Lond 1886). 1896 Jan 18;19(486):261-262. No abstract available.

Supplemental Content

Loading ...
Support Center